A subsequent study also presented a similar point; immunohistochemical analysis on tissue micro-arrays from surgically resected tumors of 122 pancreatic and 72 ampullary cancer patients revealed HHLA2 expression in 67% of pancreatic and 93% of ampullary tumors, associating enhanced expression with improved post-surgical outcomes, including delayed cancer recurrence and improved cancer-specific survival (Boor et al., 2020). The gene discussed is HHLA2; the disease is cancer.